1
Guriq Basi, Jack Steven Jacobsen: Humanized antibodies that recognize beta amyloid peptide. Janssen Alzheimer Immunotherapy, Townsend and Townsend and Crew, December 1, 2009: US07625560 (31 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.


2
Nicholas W Warne, Donna Luisi, Angela Kantor: Anti Aβ antibody formulation. Janssen Alzheimer Immunotherapy, Wyeth, Townsend and Townsend and Crew, December 22, 2009: US07635473 (19 worldwide citation)

The present invention provides formulations for maintaining the stability of Aβ binding polypeptides, for example, Aβ antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidan ...


3
Ranganathan Godavarti, Timothy Iskra: Methods of purifying Fc region containing proteins. Janssen Alzheimer Immunotherapy, Wyeth, Alston & Bird, October 26, 2010: US07820799 (17 worldwide citation)

The present application provides methods of purifying polypeptides having a Fc region, for example, antibodies or antibody fusions, by adsorbing the polypeptides to a Fc binding agent, such as, for example, Protein A or Protein G, followed by a wash with a divalent cation salt buffer to remove impur ...


4
Guriq Basi, Jose Saldanha, Frédérique Bard: Humanized antibodies that recognize beta amyloid peptide. Janssen Alzheimer Immunotherapy, Wyeth, Alston and Bird, January 18, 2011: US07871615 (14 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.


5
Dale B Schenk: Humanized antibodies that recognize beta amyloid peptide. Janssen Alzheimer Immunotherapy, Alston & Bird, February 22, 2011: US07893214 (13 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.


6
Dale B Schenk, Eliezer Masliah: Treatment and delay of outset of Parkinsons disease. Janssen Alzheimer Immunotherapy, The Regents Of The University Of California, Townsend and Townsend and Crew, June 1, 2010: US07727957 (13 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. Th ...


7
Dale B Schenk: Prevention and treatment of amyloidogenic disease. Janssen Alzheimer Immunotherapy, Alston & Bird, October 11, 2011: US08034339 (12 worldwide citation)

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of A ...


8
Dale B Schenk: Prevention and treatment of amyloidgenic disease. Janssen Alzheimer Immunotherapy, Alston & Bird, June 21, 2011: US07964192 (11 worldwide citation)

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of A ...


9
Guriq Basi, Jose William Saldanha, Dale B Schenk: Humanized antibodies that recognize β-amyloid peptide. Janssen Alzheimer Immunotherapy, Wyeth, Townsend and Townsend and Crew, April 20, 2010: US07700751 (11 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.


10
Dale B Schenk: Humanized antibodies that recognize beta amyloid peptide. Janssen Alzheimer Immunotherapy, Townsend and Townsend and Crew, September 7, 2010: US07790856 (8 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.